Telo Genomics Corp (TELO) - Total Assets
Based on the latest financial reports, Telo Genomics Corp (TELO) holds total assets worth CA$606.90K CAD (≈ $439.02K USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Telo Genomics Corp - Total Assets Trend (2012–2025)
This chart illustrates how Telo Genomics Corp's total assets have evolved over time, based on quarterly financial data. Also see Telo Genomics Corp stock valuation for the company's overall valuation and market capitalisation.
Telo Genomics Corp - Asset Composition Analysis
Current Asset Composition (June 2025)
Telo Genomics Corp's total assets of CA$606.90K consist of 97.9% current assets and 2.1% non-current assets. Review total liabilities of Telo Genomics Corp to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 86.6% |
| Accounts Receivable | CA$26.54K | 2.9% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$0.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2012–2025)
This chart illustrates how Telo Genomics Corp's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Telo Genomics Corp stock quote for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Telo Genomics Corp's current assets represent 97.9% of total assets in 2025, an increase from 71.0% in 2012.
- Cash Position: Cash and equivalents constituted 86.6% of total assets in 2025, up from 71.0% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 2.9% of total assets.
Telo Genomics Corp Competitors by Total Assets
Key competitors of Telo Genomics Corp based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$1.38 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Avricore Health Inc
V:AVCR
|
Canada | CA$584.37K |
Telo Genomics Corp - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.93 | 0.99 | 9.17 |
| Quick Ratio | 0.93 | 0.99 | 9.17 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$-45.05K | CA$-4.08K | CA$1.54 Million |
Telo Genomics Corp - Advanced Valuation Insights
This section examines the relationship between Telo Genomics Corp's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.26 |
| Latest Market Cap to Assets Ratio | 3.19 |
| Asset Growth Rate (YoY) | -5.6% |
| Total Assets | CA$911.30K |
| Market Capitalization | $2.91 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Telo Genomics Corp's assets at a significant premium (3.19x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Telo Genomics Corp's assets decreased by 5.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Telo Genomics Corp (2012–2025)
The table below shows the annual total assets of Telo Genomics Corp from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | CA$911.30K ≈ $659.22K |
-5.63% |
| 2024-06-30 | CA$965.64K ≈ $698.53K |
-66.99% |
| 2023-06-30 | CA$2.93 Million ≈ $2.12 Million |
+3.26% |
| 2022-06-30 | CA$2.83 Million ≈ $2.05 Million |
-26.20% |
| 2021-06-30 | CA$3.84 Million ≈ $2.78 Million |
+228.51% |
| 2020-06-30 | CA$1.17 Million ≈ $845.40K |
+344.92% |
| 2019-06-30 | CA$262.67K ≈ $190.01K |
-38.85% |
| 2018-06-30 | CA$429.51K ≈ $310.70K |
-86.20% |
| 2017-06-30 | CA$3.11 Million ≈ $2.25 Million |
+417.66% |
| 2016-06-30 | CA$601.32K ≈ $434.98K |
+29.17% |
| 2015-06-30 | CA$465.54K ≈ $336.76K |
-9.54% |
| 2014-06-30 | CA$514.62K ≈ $372.27K |
-6.22% |
| 2013-06-30 | CA$548.76K ≈ $396.97K |
+452.25% |
| 2012-06-30 | CA$99.37K ≈ $71.88K |
-- |
About Telo Genomics Corp
Telo Genomics Corp., a molecular diagnostics company, engages in the development and commercialization of predictive technological products to personalize treatment plans for patients with specific conditions, primarily in Canada. The company's TeloView platform measures the 3D structure and spatial organization of telomeres to inform on genetic and molecular characteristics that are predictive o… Read more